Summary
Guardant Health, Inc. (GH) filed an 8-K on January 9, 2023, primarily to announce preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2022. The company also indicated that a presentation for the 2023 J.P. Morgan Healthcare Conference would be made available on their investor website. Investors should note that the financial information provided in this filing is preliminary and unaudited, meaning it is subject to change after a full audit. The details of the actual financial performance are expected to be in the press release (Exhibit 99.1) and the investor presentation.
Key Highlights
- 1Guardant Health provided preliminary, unaudited financial results for Q4 and Full Year 2022.
- 2A press release containing these preliminary results is furnished as Exhibit 99.1.
- 3The company will post its presentation from the 2023 J.P. Morgan Healthcare Conference on its website.
- 4The information furnished is not deemed 'filed' for regulatory purposes under Section 18 of the Exchange Act.
- 5Investors should refer to Exhibit 99.1 and the upcoming investor presentation for detailed financial information.
- 6This filing signals upcoming financial disclosure and investor communication from Guardant Health.
Frequently Asked Questions
The main purpose of this 8-K filing is to announce preliminary, unaudited financial results for the fourth quarter and full year 2022, and to disclose that an investor presentation for the J.P. Morgan Healthcare Conference will be available on the company's website.
The preliminary financial results are detailed in the press release, which is furnished as Exhibit 99.1 to this 8-K filing. You can access this exhibit through the SEC's EDGAR database or the Guardant Health investor relations website.
No, the financial information provided is preliminary and unaudited. This means it has not yet undergone a full audit by an independent auditor and may be subject to adjustments.
This filing primarily provides preliminary results. Specific guidance or outlook for future periods would typically be discussed in the accompanying press release (Exhibit 99.1) or the investor presentation for the J.P. Morgan Healthcare Conference, which should be reviewed for more forward-looking statements.